EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo‐controlled exploratory study

Juan Carlos Garcia-Pagan, Lise Lotte Gluud, Mattias Mandorfer, Jörn M Schattenberg, Andrea De Gottardi, Annalisa Berzigotti, José Ignacio Fortea, Agustin Albillos Martínez, Edilmar Alvarado-Tapias, Marco Berning, Pawel Petryszyn, Emilia Henricson und 8 weitere

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70332 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Juan Carlos Garcia-Pagan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). CIBEREHD …. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Liver Cirrhosis, Glucosides, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 51 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Endothelin A (ET A ) receptor antagonists may reduce cirrhosis‐associated portal hypertension (PH). They are associated with fluid retention, which might be mitigated by sodium–glucose co‐transporter 2 inhibitors (SGLT2is). Efficacy, safety and tolerability of combining the selective ET A receptor antagonist zibotentan and the selective SGLT2i dapagliflozin were investigated.

Methods

Patients with compensated cirrhosis (Child‐Pugh A) were randomized 1:1 to zibotentan 2.5 mg plus dapagliflozin 10 mg (zibo/dapa) or placebo in a 6‐week parallel, double‐blind Phase II study. The absolute change in hepatic venous pressure gradient (HVPG) from baseline to week 6 was evaluated in the full analysis set using analysis of covariance.

Results

In 28 participants (n = 14 per group), median age was 64 years (range: 37–78), common causes of cirrhosis were metabolic dysfunction‐associated steatotic (46%) or alcohol‐associated liver disease (39%), and 46% were receiving stable doses of non‐selective beta‐blockers. Baseline HVPG was 6.5–19 mmHg, and 16/28 had clinically significant portal hypertension. Absolute change in HVPG at week 6 was not different between groups (1.02 mmHg [90% CI −0.31, 2.35]). There was a trend towards decreased HVPG in patients with baseline HVPG ≥12 mmHg receiving zibo/dapa. Systolic and diastolic blood pressure were also reduced by zibo/dapa vs . placebo. Three mild adverse events (peripheral oedema) were reported (zibotentan/dapagliflozin, n = 2; placebo, n = 1). No serious adverse events or drug‐induced liver injuries were observed.

Conclusions

Combined zibo/dapa was well tolerated and had a good safety profile in patients with compensated cirrhosis, but had no conclusive effect on HVPG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsLiver CirrhosisGlucosidesSodium-Glucose Transporter 2 InhibitorsHypertension, PortalEndothelin A Receptor AntagonistsHumansMiddle AgedMaleFemaleDouble-Blind MethodAgedAdultDrug Therapy, CombinationTreatment OutcomePortal Pressure

Stichwörter der Autor:innen

Child‐Pugh AETA receptor antagonistSGLT2 inhibitorhepatic venous pressure gradient

Substanzen

Benzhydryl CompoundsGlucosidesdapagliflozinSodium-Glucose Transporter 2 InhibitorsEndothelin A Receptor Antagonists

Autor:innen und Institutionen

  • Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). CIBEREHD (Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Dig…
  • Gastro Unit, Copenhagen University Hospital Hvidovre and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Department of Internal Medicine II, Saarland University Medical Center, Homburg, Germany.
  • Gastroenterology and Hepatology, Luzerner Kantonsspital, Luzern, Switzerland.
  • Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

ORCID-Profile: Don C Rockey

Förderung

  • AstraZeneca

Zitieren

APA

Garcia-Pagan, J. C., Gluud, L. L., Mandorfer, M., Schattenberg, J. M., De Gottardi, A., Berzigotti, A., Fortea, J. I., Martínez, A. A., Alvarado-Tapias, E., Berning, M., Petryszyn, P., Henricson, E., Berglind, N., Lin, M., Persson, K., Mercier, A. K., Ambery, P., Bosch, J., Oscarsson, J., & Rockey, D. C. (2025). Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo‐controlled exploratory study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70332

Vancouver

Garcia-Pagan JC, Gluud LL, Mandorfer M, Schattenberg JM, De Gottardi A, Berzigotti A, et al. Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo‐controlled exploratory study. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70332

BibTeX
@article{GarciaPagan2025,
  author = {Garcia-Pagan, Juan Carlos and Gluud, Lise Lotte and Mandorfer, Mattias and Schattenberg, Jörn M and De Gottardi, Andrea and Berzigotti, Annalisa and Fortea, José Ignacio and Martínez, Agustin Albillos and Alvarado-Tapias, Edilmar and Berning, Marco and Petryszyn, Pawel and Henricson, Emilia and Berglind, Niklas and Lin, Min and Persson, Kevin and Mercier, Anne-Kristina and Ambery, Phil and Bosch, Jaime and Oscarsson, Jan and Rockey, Don C},
  title = {Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo‐controlled exploratory study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70332}
}
Kostenlos starten →